SMS Pharmaceuticals receives EIR from USFDA for API facility in Andhra Pradesh

12 Mar 2020 Evaluate

SMS Pharmaceuticals has received Establishment Inspection Report (EIR) from United States Food and Drug Administration (USFDA) for its API facility situated at Kandivalasa, Andhra Pradesh. The USFDA had inspected the said facility during the period January 13, 2020 to January 17, 2020. This facility predominantly caters regulated markets including USA.

SMS Pharmaceuticals is a global player in API manufacturing having strong research and manufacturing team supported by state of art facilities.

SMS Pharmaceuticals Share Price

311.75 -1.55 (-0.49%)
31-Dec-2025 12:45 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1719.05
Dr. Reddys Lab 1266.30
Cipla 1501.90
Zydus Lifesciences 913.75
Lupin 2104.05
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×